Key result
Carriage of at least 1 reduced-function CYP2C19 allele was associated with a significantly increased risk of major adverse cardiovascular events in patients on clopidogrel for PCI.
Why the study?
Does carriage of a reduced-function CYP2C19 allele increase the risk of major adverse cardiovascular events in patients treated with clopidogrel for PCI?
Does carriage of a reduced-function CYP2C19 allele increase the risk of major adverse cardiovascular events in patients treated with clopidogrel for PCI?
Carriage of a reduced-function CYP2C19 allele significantly increases the risk of MACE and stent thrombosis in patients receiving clopidogrel for PCI.
May support CYP2C19 testing in clopidogrel-treated PCI patients; leaves open whether genotype-guided therapy improves outcomes.
Among patients treated with clopidogrel for percutaneous coronary intervention, carriage of even 1 reduced-function CYP2C19 allele appears to be associated with a significantly increased risk of major adverse cardiovascular events, particularly stent thrombosis.
No takes yet. Share an insight, caveat, or question.
Mega et al. (2010) studied this question. Carriage of at least 1 reduced-function CYP2C19 allele was associated with a significantly increased risk of major adverse cardiovascular events in patients on clopidogrel for PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: